Changes are afoot to meet higher caseloads amid rising demand, the survey of 6,830 cardiovascular providers suggests.

Bioadaptor was designed to restore normal vessel function and reduce late stent-related complications. It’s working so far.

The national coverage determination explicitly outlines patient, clinician, and facilities criteria for qualifying procedures ...

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of ...

Mamas Mamas, Ruben de Winter, and Paul Knaapen discuss the results of the PROCTOR trial, which explored native vessel versus ...

Modern is consistent with the literature in this space, but the trial shows that a staged complete procedure might be just ...

The intracoronary fibrinolysis infusion joins a host of other failed treatments to improve microvascular obstruction after ...

Having more-thorough workup uncovered an unexpected root cause and changed the treatment course for 76% of patients.

Bioadaptor was designed to restore normal vessel function and reduce late stent-related complications. It’s working so far.

The data are largely in line with those seen at 5 years, but the follow-up reassures there’s no concern about valve ...

The device, which is delivered transapically, represents an option for very sick patients who previously have had none.

Reaching participants through retail pharmacies, the study speaks to how much VHD goes underrecognized—with a few surprises.